N/A N=51 The Relationship Between Sleep and Glucose Tolerance in Prediabetes: the Role of GLP-1 in Short Sleepers
Prediabetes
Primary: GLP-1 Levels in Response to Oral Glucose Tolerance Test — 16.66; 18.57 pmol/l.h — p=0.209
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=44 P20 Extending Sleep to Reverse Metabolic Syndrome
Metabolic Syndrome
Primary: SASI Acceptability Questionnaire Score at Pre-Intervention — 3.91 score on a scale
N/A N=31 Metabolic Effects of Sleep Extension in People With Obesity
Insulin Resistance · Obesity
Primary: Insulin Sensitivity — -3.8; 0.9 µmol/kgFFM/min
N/A N=18 Sleep Duration in Women With Previous Gestational Diabetes
Gestational Diabetes
Primary: Changes in Fasting Glucose — 10.4; 1.6 mg/dL
N/A N=20 Sleep Loss and Mechanisms of Impaired Glucose Metabolism
Primary Insomnia
Primary: Change in Glucose Tolerance (Kg) in Response to Insulin-modified Intravenous Glucose Tolerance Test — .33; -0.10 %/min, slope of natural log glucose
N/A N=16 Sleep Length and Circadian Regulation in Humans
Sleep Disorders
Primary: Dim Light Melatonin Onset (Hours) — 1.93; 0.80 hours
N/A N=452 Chronic Sleep Deprivation Among the Poor: A Lab-in-the-field Approach
Blood Pressure · Depression
Primary: Sleep Per 24 Hours — 5.61; 5.81; 5.99; 6.23 Hours of sleep/24 hours
N/A N=120 Home Sleep and Circadian Phase: Mediators of Diabetes Risk
Sleep Deprivation · Diabetes · Circadian Dysregulation
Primary: Oral Disposition Index — 11.5 None (Index) — p=.13
N/A N=6 A Sleep Intervention (SLEEP-Extend) for Young Adults At-Risk for Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Number of Enrollments in the Study Over One Year — 4; 2 Participants
N/A N=32 Metabolomics of Insomnia-Related Hyperarousal
Primary Insomnia
Primary: Number of Metabolites Elevated Relative to the Other Group. — 13; 9 Number of metabolites elevated
N/A N=18 Impact of Exenatide on Sleep in Type 2 Diabetes
Type 2 Diabetes · Sleep Disordered Breathing
Primary: Non-REM Slow Wave Sleep — 47.3; 34.3; 57.3; 41.4 minutes
N/A N=142 Delayed Sleep Timing in Teens Study
Delayed Sleep Phase
Primary: Weekday Sleep Duration - Actigraphy — 6.309; 5.866; 5.880; 5.845 Number of hours — p=0.018
N/A N=23 Long Sleep Duration and Vascular Function
Sleep
Primary: Change From Wake in Central Aortic Pulse Pressure After 11 Hours in Bed — -1.5; 0.5 mm Hg — p=0.36
N/A N=14 A Sleep Intervention in Type 1 Diabetes
Short Sleep Phenotype · Type1diabetes
Primary: Sleep Duration — 385; 388 minutes
N/A N=25 Sleep Timing and Insulin Resistance in Adolescents With Obesity
Obesity
Primary: Dim Light Melatonin Onset and Offset — 21.33; 8.32 decimal hours
N/A N=20 Poor Sleep and Inflammation in HIV-Infected Adults
HIV-1-infection · Sleep Deprivation · Inflammation
Primary: Soluble CD14 — 1290; 1196 ng/mL
N/A N=39 Sleep Promotion to Improve Diabetes Management in Adolescents With T1D
Diabetes Mellitus, Type 1
Primary: Sleep Quality: Baseline — 4.3; 4.5 score on a scale
Phase 4 N=69 Characteristics of Sleep Patterns in Young Adults With and Without Insomnia
Sleep Disorders
Primary: Change in Pittsburgh Sleep Quality Index — -0.86; -3.15; -3.32 difference score of PSQI total
N/A N=176 Triple Vulnerability? Circadian Tendency, Sleep Deprivation and Adolescence
Eveningness/Sleep
Primary: Total Sleep Time (TST) Average on Weeknights Via Daily Sleep Diary — 24.72; 13.02 Minutes — p=0.34
N/A N=845 MTNR1B SNP*Food Timing Interaction on Glucose Control
Non-Diabetic Disorder of Endocrine Pancreas
Primary: Area Under the Curve (AUC) Glucose — 278.84; 268.92; 260.66; 282.21 mg*h/dL
N/A N=65 Sleep Duration and Blood Pressure During Sleep
Blood Pressure · Hypertension · Elevated Blood Pressure
Primary: Mean Sleep Systolic Blood Pressure (BP) at Baseline and 8 Weeks — 100.8; 100.0; 101.4; 102.3 mmHg
N/A N=108 Association Between Food/Nutrient Intake and Sleep Quality in Middle Aged and Older Population
Sleep
Primary: Sleep Quality Assessment 1 (GSS) — 3.4; 8.1; 5.2 score on a scale
N/A N=191 Personalizing Sleep Interventions to Prevent Type 2 Diabetes in Community Dwelling Adults With Pre-Diabetes
PreDiabetes
Primary: Change in the Percent Time Glucose is ≥ 140 mg/dL From Pre- to Post-intervention — 0.38; -0.49 Percent time glucose >= 140mg/dL
N/A N=28 The Psychoneuroimmunology of Insomnia
Primary Insomnia
Primary: Positive Antibody Response — 7; 7 participants
N/A N=39 Self-Management in Young Adults With Type 1 Diabetes
Type 1 Diabetes
Primary: Non-dominant Wrist-worn Actigraph to be Worn 24/7 (Spectrum Plus) — 18; -25.8 min per night — p=0.0227
Phase 2 N=135 Pharmacodynamic Profile of SPD489 in Healthy Adult Males Undergoing a Nocturnal Period of Acute Sleep Loss
Sleep Deprivation
Primary: Maintenance of Wakefulness Test (MWT) — 23.3; 27.9; 29.3; 27.6 Minutes — p=<0.0001
N/A N=12 Sleep Disruption Induced Impairments in Bone Formation
Healthy
Primary: Change in Serum Pro-collagen 1 Intact N-terminal Propeptide (P1NP) — 72.1; 67.4 ng/mL — p=0.53
N/A N=45 Impact of Sleep Restriction on Performance in Adults
Sleep · Obesity · Sleep Restriction
Primary: Endpoint Fat Volume — 24.0; 24.2 Liter
N/A N=92 Sleep IntervEntion as Symptom Treatment for ADHD
ADHD · Sleep · Adolescents
Primary: Sleep Architecture Objective TST [Total Sleep Time] Pre-test to Post-test — 8.11; 7.94; 8.03; 8.07 hours — p=.17
N/A N=28 Hyper-Arousal in Chronic Primary Insomnia
Chronic Insomnia
Primary: Sympathetic Baroreflex Sensitivity (BRS) Unit — -2.1; -4.3 bursts per 100 heart beats per mm Hg